含或不含阿司匹林的固定剂量复方制剂用于心血管病一级预防:个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入TIPS-3、HOPE-3和PolyIran三项大型随机对照试验,共18162例一级预防人群,比较固定剂量复方制剂策略(至少两种降压药加他汀,含或不含阿司匹林)与对照策略。中位随访5年,主要复合终点(心血管死亡、心肌梗死、卒中或动脉血运重建)发生率在固定剂量复方制剂组为3.0%,对照组为4.9%(HR 0.62,95%CI 0.53-0.73,p<0.0001)。心肌梗死、血运重建、卒中和心血管死亡均显著降低,含阿司匹林策略的降幅更大;胃肠道出血在含阿司匹林组略多但未达统计学显著。作者认为该策略可大幅降低心血管事件,且获益在不同心血管代谢危险因素人群中一致。
要点
- 心血管病一级预防人群使用固定剂量复方制剂策略(至少两种降压药加他汀,含或不含阿司匹林),主要复合终点HR 0.62(95%CI 0.53-0.73,p<0.0001)。
- 固定剂量复方制剂策略显著降低心肌梗死(HR 0.52,95%CI 0.38-0.70)、血运重建(HR 0.54,95%CI 0.36-0.80)、卒中(HR 0.59,95%CI 0.45-0.78)和心血管死亡(HR 0.65,95%CI 0.52-0.81)。
- 含阿司匹林的固定剂量复方制剂策略较不含阿司匹林策略降幅更大;胃肠道出血在含阿司匹林组为0.4% vs 对照组0.2%(p=0.15),未达统计学显著。
- 固定剂量复方制剂组头晕更常见(11.7% vs 9.2%,p<0.0001),出血性卒中、致命性出血和消化性溃疡病发生率低且组间无显著差异。
- 治疗效应在不同血脂和血压水平、有无糖尿病、吸烟或肥胖的预设亚组中相似。
适用人群与场景
- 心血管病一级预防人群,来自TIPS-3、HOPE-3和PolyIran三项随机对照试验,共18162例参与者,平均年龄63.0岁(SD 7.1),女性9038例(49.8%),估计10年心血管病风险17.7%(SD 8.7)。
诊断标准与关键阈值
- 纳入标准:大型随机对照试验(每项≥1000例参与者且随访≥2年),评估固定剂量复方制剂策略(至少两种降压药加他汀,含或不含阿司匹林)与对照策略(安慰剂或常规治疗)比较,用于心血管病一级预防人群。
研究设计与关键结果
- 研究类型:个体参与者数据荟萃分析,纳入TIPS-3、HOPE-3和PolyIran三项大型随机对照试验,共18162例参与者。
- 主要终点:中位随访5年,固定剂量复方制剂策略组主要复合终点(心血管死亡、心肌梗死、卒中或动脉血运重建)发生276例(3.0%),对照组445例(4.9%),HR 0.62(95%CI 0.53-0.73,p<0.0001)。
- 次要终点:心肌梗死HR 0.52(95%CI 0.38-0.70),血运重建HR 0.54(95%CI 0.36-0.80),卒中HR 0.59(95%CI 0.45-0.78),心血管死亡HR 0.65(95%CI 0.52-0.81)。
- 亚组分析:含阿司匹林和不含阿司匹林的固定剂量复方制剂策略均显著降低主要终点及其组分,含阿司匹林策略降幅更大;治疗效应在不同血脂和血压水平、有无糖尿病、吸烟或肥胖的亚组中相似。
- 不良事件:胃肠道出血在含阿司匹林的固定剂量复方制剂组19例(0.4%) vs 对照组11例(0.2%),p=0.15;出血性卒中10例(0.2%) vs 15例(0.3%),致命性出血2例(<0.1%) vs 4例(0.1%),消化性溃疡病32例(0.7%) vs 34例(0.8%),均低且无显著差异;头晕在固定剂量复方制剂组更常见(1060例[11.7%] vs 834例[9.2%],p<0.0001)。
证据类型、等级与局限
- 证据类型:个体参与者数据荟萃分析,纳入三项大型随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,固定剂量复方制剂策略可大幅降低心血管病一级预防人群的心血管病、心肌梗死、卒中、血运重建和心血管死亡,且获益与心血管代谢危险因素无关。
- 含阿司匹林的固定剂量复方制剂策略降幅更大,但胃肠道出血略多(0.4% vs 0.2%,p=0.15),头晕更常见(11.7% vs 9.2%,p<0.0001)。
指南或共识出处
- Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis(Lancet)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In randomised controlled trials, fixed-dose combination treatments (or polypills) have been shown to reduce a composite of cardiovascular disease outcomes in primary prevention. However, whether or not aspirin should be included, effects on specific outcomes, and effects in key subgroups are unknown.
METHODS: We did an individual participant data meta-analysis of large randomised controlled trials (each with ≥1000 participants and ≥2 years of follow-up) of a fixed-dose combination treatment strategy versus control in a primary cardiovascular disease prevention population. We included trials that evaluated a fixed-dose combination strategy of at least two blood pressure lowering agents plus a statin (with or without aspirin), compared with a control strategy (either placebo or usual care). The primary outcome was time to first occurrence of a composite of cardiovascular death, myocardial infarction, stroke, or arterial revascularisation. Additional outcomes included individual cardiovascular outcomes and death from any cause. Outcomes were also evaluated in groups stratified by the inclusion of aspirin in the fixed-dose treatment strategy, and effect sizes were estimated in prespecified subgroups based on risk factors. Kaplan-Meier survival curves and Cox proportional hazard regression models were used to compare strategies.
FINDINGS: Three large randomised trials were included in the analysis (TIPS-3, HOPE-3, and PolyIran), with a total of 18 162 participants. Mean age was 63·0 years (SD 7·1), and 9038 (49·8%) participants were female. Estimated 10-year cardiovascular disease risk for the population was 17·7% (8·7). During a median follow-up of 5 years, the primary outcome occurred in 276 (3·0%) participants in the fixed-dose combination strategy group compared with 445 (4·9%) in the control group (hazard ratio 0·62, 95% CI 0·53-0·73, p<0·0001). Reductions were also observed for the separate components of the primary outcome: myocardial infarction (0·52, 0·38-0·70), revascularisation (0·54, 0·36-0·80), stroke (0·59, 0·45-0·78), and cardiovascular death (0·65, 0·52-0·81). Significant reductions in the primary outcome and its components were observed in the analyses of fixed-dose combination strategies with and without aspirin, with greater reductions for strategies including aspirin. Treatment effects were similar at different lipid and blood pressure levels, and in the presence or absence of diabetes, smoking, or obesity. Gastrointestinal bleeding was uncommon but slightly more frequent in the fixed-dose combination strategy with aspirin group versus control (19 [0·4%] vs 11 [0·2%], p=0·15). The frequencies of haemorrhagic stroke (10 [0·2%] vs 15 [0·3%]), fatal bleeding (two [<0·1%] vs four [0·1%]), and peptic ulcer disease (32 [0·7%] vs 34 [0·8%]) were low and did not differ significantly between groups. Dizziness was more common with fixed-dose combination treatment (1060 [11·7%] vs 834 [9·2%], p<0·0001).
INTERPRETATION: Fixed-dose combination treatment strategies substantially reduce cardiovascular disease, myocardial infarction, stroke, revascularisation, and cardiovascular death in primary cardiovascular disease prevention. These benefits are consistent irrespective of cardiometabolic risk factors.
FUNDING: Population Health Research Institute.
参考来源
- Joseph P, Roshandel G, Gao P, et al. Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. Lancet. 2021. PMID: 34469765. doi:10.1016/S0140-6736(21)01827-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。